Metrics to compare | ANTH | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipANTHPeersSector | |
|---|---|---|---|---|
P/E Ratio | 0.0x | −1.6x | −0.3x | |
PEG Ratio | 0.00 | 0.00 | 0.00 | |
Price/Book | 0.0x | 2.4x | 2.6x | |
Price / LTM Sales | 0.0x | 6.8x | 2.8x | |
Upside (Analyst Target) | 0.0% | 203.8% | 64.7% | |
Fair Value Upside | Unlock | 12.9% | 9.6% | Unlock |
Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs. It develops Sollpura, a non-porcine investigational pancreatic enzyme replacement therapy that is in Phase III clinical trial for the treatment of patients with exocrine pancreatic insufficiency; and Blisibimod, which is in Phase II clinical trial for the treatment of B-cell mediated autoimmune diseases, including immunoglobulin A nephropathy or IgA nephropathy. The company has license agreements with Amgen, Inc., and Eli Lilly and Company. Anthera Pharmaceuticals, Inc. was founded in 2004 and is based in Houston, Texas.